Sio Gene Therapies is a clinical-stage company that is dedicated to pushing the boundaries of gene therapy. Their main focus is developing innovative treatments for debilitating rare neurodegenerative diseases like GM1 gangliosidosis and Tay-Sachs/Sandhoff disease. With a strong foundation in scientific expertise, Sio leverages years of research and collaboration with leading gene therapy institutes to create flexible vector platforms that can liberate patients from these life-altering diseases.

Their mission is simple: to combine cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Sio Gene Therapies is actively working to advance their rare fatal pediatric neurodegenerative programs through clinical development, ensuring that patients have access to the life-changing therapies they need. Led by Chief Executive Officer, Chief Financial Officer, and General Counsel David Nassif, Sio Gene Therapies strives to revolutionize the field of gene therapies and provide hope to those in need